N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Phase 2 N=127 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Gout
Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
N/A N=43 The Diet Gout Trial
Gout · Hyperuricemia
Primary: Uric Acid Level — 8.23; 8.03 mg/dL
Phase 3 N=760 Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Gout
Primary: Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) — 53; 62; 21 Percentage of subjects — p=<0.001
Phase 4 N=152 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 71.0; 38.5 percentage of participants — p=< 0.0001
Phase 3 N=1,072 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Gout
Primary: Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). — 48; 65; 69; 22 Percentage of subjects — p=<0.001
Phase 4 N=13 Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
Uncontrolled Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants
Phase 3 N=248 PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares
Phase 4 N=35 Does Allopurinol Prolong a Treated, Acute Gout Flare?
Gout
Primary: Resolution of the Acute Gout Attack — 15.4; 13.4 days — p=0.5
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 2 N=143 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Gout · Hyperuricemia
Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Phase 4 N=15 Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6 — 78.6 percentage of participants
Phase 3 N=225 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001
Phase 4 N=196 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
Gout
Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298
Phase 3 N=214 Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Gout
Primary: Number of Subjects With an sUA Level That is < 6.0 mg/dL — 32; 2 Number of Subjects — p=<0.0001
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
Phase 3 N=1,315 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Gout
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants
Phase 4 N=20 Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
Uncontrolled Gout · Kidney Transplant
Primary: Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6 — 88.9 percentage of participants
Phase 2 N=200 Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Acute Gout
Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…
Phase 3 N=185 MPC-004 for the Treatment of an Acute Gout Flare
Gout
Primary: Responders — 17; 28; 9 Participants
Phase 4 N=1,732 Allopurinol Outcome Study
Gout
Primary: Safety of Allopurinol — 55.1 percentage of subjects
Phase 3 N=143 Open-Label Lesinurad Monotherapy Extension Study in Gout
Gout
Primary: Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL — 68 Subjects
Phase 3 N=241 PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Intercritical Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant